Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Shreyans Gandhi, MBBS,MDDNB,MRCP,FRCPath,MPhil, Jie Jiang, PhD, Simon Slade, BSc, Austin Kulasekararaj, MD MRCP, FRCPath, Victoria Potter, BSc, MBBS, FRCPA, Varun Mehra, MBBS,MRCP,FRCPath, Petra Muus, MD PhD, Andrea Da Silva, MBBS, Sudarshan Gurung, MBBS, MRCP, Alice Mason, B.Pharm, Aytug Kizilors, PhD, Nicholas Lea, PhD, Sahar Mansour, MD, Robin M. Ireland, MBBS, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Judith Marsh, MD FRCPath

Blood (2019) 134 (Supplement_1): 3749.

https://doi.org/10.1182/blood-2019-130754

Published: 2019

Journal Articles

Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients

Aytug Kizilors, PhD, Patrick Harrington, FRCPath, MRCP, Sophie Jackson, BSc, Nicholas Lea, PhD, Joel Newman, MBBS, MRCP, BSc, FRCPath, Richard Gale, FRCPath, FRCP, Sandra Hassan, MD, Evangelia Dimitriadou, MD, Elena Crisà, MD, Luke Ficinski, BSc, Isabel Sa, BSc, Anita Arasaretnam, MD, Vijayavalli Dhanapal, MD, Timothy Corbett, FRCP, FRCPath, Robin M. Ireland, FRCP, Antonio Pagliuca, Ghulam J. Mufti, Hugues De Lavallade

Blood (2018) 132 (Supplement 1): 3025.

https://doi.org/10.1182/blood-2018-99-118905

Published: 2018

Journal Articles

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Varun Mehra, MRCP, FRCPath, Titilola Oyebamiji, Stefanie Widya, Robin M. Ireland, FRCP, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Kavita Raj, MD PhD, Donal McLornan, Judith Marsh, MD, Victoria Potter, Joanna Large, Isabel Duggins, Aytug Kizilors, PhD, Nicholas Lea, PhD, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath, Hugues De Lavallade

Blood (2017) 130 (Supplement 1): 5250.

https://doi.org/10.1182/blood.V130.Suppl_1.5250.5250

Published: 2017

Journal Articles

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2 -Mutated MDS/AML

Ahad Al Seraihi, BSc, MSc, Ana Rio-Machin, BSc, MSc, PhD, Kiran Tawana, MD PhD, Csaba Bödör, BSc, PhD, Shamzah Araf, MD, James A Heward, BSc, PhD, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Sameena Iqbal, Steven Best, PhD, Nicholas Lea, PhD, Donal McLornan, MB, Bch (Hons), PhD MRCP, FRCPath, Alicia Ellison, BSc, Hemanth Tummala, PhD, Shirleny Romualdo Cardoso, BSc, Jamie D. Cavenagh, Tom Vulliamy, FRCPath, Inderjeet Dokal, MD FRCPCH, FRCPath, FMedSci, Jude Fitzgibbon

Blood (2016) 128 (22): 3916.

https://doi.org/10.1182/blood.V128.22.3916.3916

Published: 2016

Journal Articles

Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Steven Best, PhD, Aytug Kizilors, PhD, Shreyans Gandhi, MD DNB, MRCP, FRCPath, Victoria T Potter, Judith C. W. Marsh, MD FRCP, FRCPath, Nicholas Lea, PhD, Robin M. Ireland, FRCP, FRCPath, Ghulam J Mufti, MD

Blood (2016) 128 (22): 1981.

https://doi.org/10.1182/blood.V128.22.1981.1981

Published: 2016

Journal Articles

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Aytug Kizilors, PhD, Elena Crisa, MD, Nicholas Lea, PhD, Steven Best, PhD, Mian Syed, PhD, Robin M. Ireland, FRCP, FRCPath, Maadh Aldouri, FRCPath, Christopher Pocock, Timothy Corbett, FRCP, FRCPath, Emily Elizabeth Bart-Smith, MRCP,BSc, Richard Gale, FRCPath, FRCP, Clare Wykes, FRCPath, FRCP, Simon Weston-Smith, FRCP, FRCPath, Donal McLornan, MDPhD, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Ghulam J. Mufti, MD PhD, Hugues de Lavallade, MD PhD

Blood (2015) 126 (23): 347.

https://doi.org/10.1182/blood.V126.23.347.347

Published: 2015

Journal Articles

Immunological Profile of Patients after HSCT Using the FCC Conditioning Regimen for Treatment of Severe Aplastic Anemia Shows Sustained Mixed T-Cell Chimerism Is Due to Persistence of Recipient CD8 T Cells and Indicates Potential Basis for Tolerance and Extremely Low Incidence of Graft Versus Host Disease

Francesco Grimaldi, MD, Pilar Perez-Abellan, Steven Best, PhD, Nicholas Lea, PhD, John Veluchamy, Muhammad Atif, MD, Rosemary Grain, Monica Sen, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Antonio Pagliuca, MBBS, FRCP, FRCPath, MA, Victoria T Potter, MD FRCPA, FRACP, Ghulam J Mufti, FRCP, FRCPath, Judith C.W. Marsh, MD, Linda D Barber, PhD

Blood (2015) 126 (23): 3129.

https://doi.org/10.1182/blood.V126.23.3129.3129

Published: 2015

Journal Articles

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

Elena Crisà, MD, Esperanza Such, PhD, Steven Best, PhD, Austin Kulasekararaj, José Cervera, Vera Adema, PhDstudent, Nicholas Lea, PhD, Dario Ferrero, MD PhD, Bernardino Allione, Julie Schanz, MD PhD, Detlef Haase, MD, Guillermo F. Sanz, MD PhD, Francesco Sole, PhD, Ghulam J. Mufti, MD PhD

Blood (2014) 124 (21): 4662.

https://doi.org/10.1182/blood.V124.21.4662.4662

Published: 2014

Journal Articles

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Ghulam J Mufti, FRCP, FRCPath, MD, Steven Best, PhD, Nicholas Lea, PhD, Lewis R. Silverman, MD, Guillermo Garcia-Manero, MD, Nozar Azarnia, PhD, Francois Wilhelm, MD PhD, Gudrun Goehring, MD

Blood (2014) 124 (21): 3258.

https://doi.org/10.1182/blood.V124.21.3258.3258

Published: 2014

Journal Articles

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Blood (2014) 124 (21): 2374.

https://doi.org/10.1182/blood.V124.21.2374.2374

Published: 2014

Journal Articles

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

Austin G. Kulasekararaj, Azim M Mohamedali, PhD, Alexander E Smith, PhD, Syed A Mian, Nazia Matto, Terry J Gaymes, DPhil, Nicholas Lea, PhD, Joop Gaken, PhD, Ghulam J. Mufti, DM, FRCP, FRCPath

Blood (2013) 122 (21): 2792.

https://doi.org/10.1182/blood.V122.21.2792.2792

Published: 2013

Journal Articles

High Resolution Genomic Mapping of Breast Cancer Derived T-MDS/TAML

Azim M Mohamedali, PhD, Natalie Twine, MSc, Joop Gaken, PhD, Nigel Westwood, PhD, CSci, FIBMS, Nicholas Lea, PhD, Rajani Chelliah, MSc, Detlef Haase, MD, PhD, Ghulam J Mufti, FRCP, FRCPath

Blood (2008) 112 (11): 2692.

https://doi.org/10.1182/blood.V112.11.2692.2692

Published: 2008

Journal Articles

MicroRNA Expression Profiling of High and Low Risk MDS

Joop Gaken, PhD, Azim M Mohamedali, PhD, Natalie Twine, Nigel Westwood, PhD, CSCI, FIBMS, Barbara Czepulkowski, Saousan Chehade, Lynn S Quek, Nicholas Lea, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2008) 112 (11): 3645.

https://doi.org/10.1182/blood.V112.11.3645.3645

Published: 2008

Journal Articles

High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy

Azim M Mohamedali, PhD, Nicholas Lea, PhD, Natalie Twine, MSc, Joop Gaken, PhD, Rajani Chelliah, MSc, Nigel Westwood, PhD, CSci, FIBMS, Ghulam J Mufti, FRCP, FRCPath

Blood (2008) 112 (11): 225.

https://doi.org/10.1182/blood.V112.11.225.225

Published: 2008

Journal Articles

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Raj K. Patel, MD, Nicholas Lea, PhD, Michael A. Heneghan, MD, Nigel Westwood, PhD, Dragana Milojkovic, MD, Kumar Thanigaikumar, MD, Deborah Yallop, MD, Roopen Arya, PhD, Antonio Pagliuca, MD, Joop Gaken, PhD, Nigel A. Heaton, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2588.

https://doi.org/10.1182/blood.V106.11.2588.2588

Published: 2005

Journal Articles

Increased DNA Damage and Error-Prone Repair in MPD/MDS Mice with Disease Progression: Key Indicators for Increased Genomic Instability.

Feyruz V. Rassool, PhD, Terry J. Gaymes, PhD, Nicola Brady, PhD, Nicholas Lea, PhD, Marika Pla, PhD, Thi Hai Phan, PhD, Scott Kogan, MD, Christine Chomienne, MDPhD, Nicholas S. Thomas, PhD, Ghulam J. Mafti, MD, Rose Ann Padua, PhD

Blood (2004) 104 (11): 200.

https://doi.org/10.1182/blood.V104.11.200.200

Published: 2004

NARROW

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Telomeric Length to Characterize and Prognosticate Bone Marrow Failure, Risk of Clonal Evolution and Multi-System Complications in Aplastic Anemia and Other Hypocellular Cytopenic Disorders, Independent of Telomere Gene Complex Mutations

Clinical Intervention Using NGS-Based Kinase Domain Mutation Testing in CML Patients

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Variable Penetrance Is Linked with Monoallelic Gene Expression in Inherited GATA2 -Mutated MDS/AML

Targeted Sequencing of 647 Patients with Myeloid Malignancies, Marrow Failures and Cytopenia: A Prospective Analysis

Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Comprehensive Mutational Screening Of 5-Azacitidne Treated Myelodysplastic Syndrome (MDS) Patients Fails To Identify a Specific Mutational Profile Predicting Response To Therapy

High Resolution Genomic Mapping of Breast Cancer Derived T-MDS/TAML

MicroRNA Expression Profiling of High and Low Risk MDS

High Resolution Molecular Analysis of 5q- Syndrome Patients at Diagnosis and Following Lenalidomide Therapy

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Increased DNA Damage and Error-Prone Repair in MPD/MDS Mice with Disease Progression: Key Indicators for Increased Genomic Instability.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only